GSK Faces Tough Scrutiny from Delaware Judges in Zantac Appeal

In a recent appeal involving GlaxoSmithKline (GSK) and the controversial acid-reflux drug Zantac, a panel of judges in Delaware posed challenging questions that could significantly impact the pharmaceutical giant's defense. The case has sparked intense interest due to Zantac's alleged link to cancer, with thousands of lawsuits arising from claims that the medication contained unsafe levels of a substance that was later identified as potentially carcinogenic.

Continue reading

FDA Imposes Ban on Controversial Red No. 3 Dye Linked to Cancer Risks

In a significant regulatory move, the U.S. Food and Drug Administration (FDA) has officially banned the use of the red No. 3 dye, a synthetic colorant commonly found in various food products, cosmetics, and personal care items. This action comes in response to growing concerns about the dye's potential carcinogenic effects, which have been increasingly scrutinized by health experts and researchers alike.

Continue reading